Dare Bioscience Secures Strategic Autonomy with Key Asset Reversion

Dare Bioscience has regained full strategic control over its most promising clinical candidate. The company has taken back the commercial rights to Ovaprene, its hormone-free contraceptive, a move that grants it complete autonomy over the drug's future. This strategic shift coincides with the early commercial rollout of another product, drawing investor attention to nearer-term revenue potential.

While advancing its pipeline, Dare Bioscience is implementing a strategy to generate more immediate cash flow. Central to this effort is the commercial launch of its topical Sildenafil cream, marketed as DARE to PLAY™. Following a pre-order phase that commenced in December 2025, the product is now being distributed through specialized channels.

This topical formulation is designed to enhance blood flow and represents a key component of the company's plan to establish a revenue stream. The financial foundation is further bolstered by non-dilutive capital in the form of government grant funding. These funds are allocated directly to support research and development across Dare's portfolio of women's health programs.

A Pivotal Milestone for Ovaprene

The reversion of full commercial rights to Ovaprene became effective this month. Ovaprene is a monthly-use, hormone-free intravaginal ring. By concluding its previous licensing partnership, Dare now independently directs the ongoing Phase 3 clinical trial and will manage any future market introduction.

Should investors sell immediately? Or is it worth buying Dare Bioscience?

This move comes amid growing global interest in alternatives to traditional hormonal contraceptives. By focusing on non-hormonal solutions, Dare aims to strengthen its position for potential future global partnerships. The company is targeting the completion of patient recruitment for the crucial Phase 3 study by the end of 2026.

Key Developments and Forward Timeline

The coming months will be defined by clinical progress. With the goal of finalizing Ovaprene study enrollment in 2026, a critical milestone for the regulatory pathway is approaching.

The essential details for investors are:
* The return of Ovaprene rights is effective as of February 2026.
* Completion of Phase 3 patient recruitment is anticipated before the close of 2026.
* The launch of the Sildenafil cream is underway to provide short-term revenue generation.